Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia

Next Previous
X
Search
Trial Profile

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plozasiran (Primary)
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Acronyms MUIR
  • Sponsors Arrowhead Pharmaceuticals

    • Most Recent Events

    • 18 Nov 2024 According to an Arrowhead Pharmaceuticals media release, results assessing the long-term efficacy and safety data from this trial presented in oral presentations at the American Heart Association Scientific Sessions 2024 (AHA24).
    • 18 Nov 2024 Results from this trial presented in an Arrowhead Pharmaceuticals media release.
    • 28 May 2024 According to an Arrowhead Pharmaceuticals media release, data from this trial presented at New England Journal of Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top